The main established treatments of proliferative diabetic retinopathy (PDR) are panretinal photocoagulation (PRP) and anti-vascular endothelial growth factor (VEGF) injection.[1] For decades, PRP was the mainstay of treatment and was known for preventing severe visual loss in PDR.[2] In the last decade, clinical trials have reported noninferiority of anti-VEGF agents to PRP in treating patients with PDR.[3,4] Less visual field loss and less occurrence/aggravation of diabetic macular edema (DME) have been the benefits of anti-VEGF compared to PRP. Here, VEGFA is linked to diabetic macular edema.